Scholarlink

<p>Tumour-derived fucosylated exosomes (FUC-Exo) play significant roles in cancer progression. However, the functions and mechanisms of fucosylated exosome-derived miRNAs in oesophageal squamous cell carcinoma (ESCC) remain largely unknown. Using lentil lectin (LCA)-coated magnetic beads for FUC-Exo isolation, small RNA sequencing and RT-qPCR identified miR-6842-3p as a novel ESCC biomarker. In vitro and in vivo assays explored its oncogenic role and pro-angiogenic function. Dual-luciferase assays, ChIP-qPCR, western blot and rescue assays were performed to elucidate angiogenic mechanisms. miR-6842-3p is upregulated in ESCC tissues and serum FUC-Exo, significantly associated with advanced clinical stages, worse prognosis and serves as an early diagnostic biomarker for ESCC. miR-6842-3p acts as an oncogene, promoting tumour growth, metastasis and angiogenesis in ESCC. Tumour-derived fucosylated exosomal miR-6842-3p, when internalised by HUVECs, downregulates PTEN, triggering the phosphorylation of AKT and mTOR. This is followed by the inhibition of IRF1 expression, thereby downregulating CXCL10 expression and driving angiogenesis. These findings elucidate that miR-6842-3p functions as a key driver of ESCC growth, metastasis and angiogenesis. Fucosylated exosomal miR-6842-3p promotes angiogenesis by mediating the PTEN/AKT/mTOR/IRF1/CXCL10 axis, highlighting its potential as a novel biomarker and therapeutic target for ESCC.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cancer-derived fucosylated exosomal miR-6842-3p as a novel marker promotes ESCC angiogenesis and metastasis via the PTEN/AKT/mTOR/IRF1/CXCL10 axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Jianlin Chen,
  • Jing Chen,
  • Xiang Lv,
  • Xiongfeng Chen,
  • Liu Ming,
  • Xinghua Huang,
  • Fuli Wen,
  • Haijun Tang,
  • Qi Gao,
  • Chengxiu Liu,
  • Jiamiao Weng,
  • Zhixin Huang,
  • Yue Zheng,
  • Fan Lin,
  • Wenshu Chen,
  • Xiuling Shang,
  • Chundong Yu,
  • Yi Huang

摘要

Tumour-derived fucosylated exosomes (FUC-Exo) play significant roles in cancer progression. However, the functions and mechanisms of fucosylated exosome-derived miRNAs in oesophageal squamous cell carcinoma (ESCC) remain largely unknown. Using lentil lectin (LCA)-coated magnetic beads for FUC-Exo isolation, small RNA sequencing and RT-qPCR identified miR-6842-3p as a novel ESCC biomarker. In vitro and in vivo assays explored its oncogenic role and pro-angiogenic function. Dual-luciferase assays, ChIP-qPCR, western blot and rescue assays were performed to elucidate angiogenic mechanisms. miR-6842-3p is upregulated in ESCC tissues and serum FUC-Exo, significantly associated with advanced clinical stages, worse prognosis and serves as an early diagnostic biomarker for ESCC. miR-6842-3p acts as an oncogene, promoting tumour growth, metastasis and angiogenesis in ESCC. Tumour-derived fucosylated exosomal miR-6842-3p, when internalised by HUVECs, downregulates PTEN, triggering the phosphorylation of AKT and mTOR. This is followed by the inhibition of IRF1 expression, thereby downregulating CXCL10 expression and driving angiogenesis. These findings elucidate that miR-6842-3p functions as a key driver of ESCC growth, metastasis and angiogenesis. Fucosylated exosomal miR-6842-3p promotes angiogenesis by mediating the PTEN/AKT/mTOR/IRF1/CXCL10 axis, highlighting its potential as a novel biomarker and therapeutic target for ESCC.